Pharmaceutical 3D Printing

The Role of Binder Jetting in Pharmaceutical 3D Printing

As the pharmaceutical industry moves toward more flexible, patient-specific approaches to drug development and manufacturing, 3D printing has emerged as a powerful enabling technology — and binder jetting has proven to be one of the most promising processes for pharmaceutical applications specifically.

Binder jetting works by selectively depositing a liquid binder onto a bed of powder, layer by layer, to build a solid form without heat, pressure, or solvents that could compromise sensitive active pharmaceutical ingredients (APIs). This gentle, room-temperature process makes it uniquely suited to pharmaceutical formulation, where preserving API stability and controlling dose precision are critical. It's also the technology behind the first and only FDA-approved 3D-printed pharmaceutical product, which demonstrated that binder jetting can meet the rigor of regulated drug manufacturing while unlocking design possibilities — like highly porous, rapidly disintegrating tablet structures — that traditional manufacturing methods can't achieve.

As formulation science increasingly looks toward complex tablet architectures, precision dosing, and on-demand production models, binder jetting is positioned as a foundational technology for the next generation of pharmaceutical development and manufacturing.

How Additive Innovations Is Addressing This Need

Additive Innovations is bringing binder jetting into the pharmaceutical formulation lab with a system built specifically for this purpose. Rather than adapting industrial or research-grade printers not designed with pharma workflows in mind, we've developed a compact, lab-ready platform sized to fit on a benchtop or integrate directly into a vertical biosafety enclosure — bringing binder jetting capability within reach of formulation teams working in real lab environments.

This lab-scale system is intentionally designed as the first step in a longer roadmap. As formulation programs mature and demonstrate reproducible results at lab scale, our platform is built to evolve toward a GMP-ready production environment suited to compounding settings, including 503A and 503B facilities — giving development teams a clear, technology-consistent path from early-stage exploration to production without having to switch platforms or requalify processes from scratch.

Material flexibility sits at the core of this approach. Our system supports multiple independent fluid channels, aqueous and solvent-based binders, and the ability to incorporate APIs into either the powder or the fluid phase — giving formulators the freedom to explore a wide range of material strategies rather than being locked into a single binder or powder chemistry. This flexibility, combined with the inherent advantages binder jetting holds over extrusion-based and other additive processes (no thermal or mechanical stress on the material, high design freedom, and gentler handling of sensitive compounds) gives development teams a genuinely versatile tool for material development.

Perhaps most importantly, our platform makes this exploration automated and in-house. Formulation scientists can run material development and tablet architecture studies directly within their own facility, on their own timeline, without waiting on outside labs or third-party fabrication. And because the underlying binder jetting process is inherently scalable, work done at the lab stage lays the groundwork for a future transition to production-scale manufacturing on the same technological foundation.

The Benefits of 3D Printing for Pharmaceutical Development and Production

3D printing offers pharmaceutical developers a fundamentally different set of capabilities than traditional manufacturing methods, with benefits that span the full development lifecycle:

• Personalized dosing — Dose strength, release profile, and even tablet geometry can be tailored to individual patient needs rather than confined to a fixed set of standard dose strengths.

• Design freedom — Complex internal architectures, such as core-shell structures, multi-layer matrices, and channeled geometries, enable release profiles that are difficult or impossible to achieve with conventional tableting.

• Faster iteration — Formulation changes can be tested and evaluated in hours rather than the weeks or months typically required to requalify traditional tooling and processes.

• Reduced material waste — Additive processes use only the material needed to build the target form, which is especially valuable when working with costly or limited-supply APIs.

• Decentralized production potential — 3D printing enables on-demand manufacturing closer to the point of care, which can reduce inventory needs and extend the effective usable life of formulated materials.

• Streamlined path from R&D to production — Formulation work performed on additive platforms can, in principle, translate more directly to production-scale systems built on the same underlying technology, shortening the traditional development-to-manufacturing timeline.

Why Binder Jetting Outperforms Competing Additive Processes

Not all 3D printing technologies are equally suited to pharmaceutical applications. Compared to other common additive processes — particularly extrusion-based methods like fused deposition modeling (FDM) or semi-solid extrusion — binder jetting offers several distinct advantages for pharma:

• No heat required — Extrusion-based processes rely on thermal energy to melt or soften material, which can degrade heat-sensitive APIs and limit the range of compatible formulations. Binder jetting operates at room temperature, preserving API integrity across a much broader range of compounds.

• No mechanical stress on the API — Extrusion subjects material to shear forces during processing. Binder jetting's powder-and-binder approach avoids this stress entirely, which matters for fragile or structurally sensitive molecules.

• Greater formulation flexibility — Binder jetting decouples the powder (excipient/API matrix) from the binder (fluid), allowing independent optimization of each — something extrusion-based single-material or single-filament approaches cannot easily replicate.

• Higher achievable porosity and disintegration control — The powder-bed approach naturally supports highly porous structures, enabling rapidly disintegrating or precisely controlled-release tablet designs that are difficult to reproduce with extrusion.

• Multi-material printing in a single build — Multiple binders (and multiple APIs) can be deposited within a single print, enabling combination products and complex dosing strategies that would require multiple extrusion passes or post-processing steps.

• Established regulatory precedent — Binder jetting is the process behind the first FDA-approved 3D-printed drug product, giving development teams a proven regulatory pathway to build from rather than a purely novel one.

Taken together, these characteristics make binder jetting one of the most pharma-ready 3D printing technologies available today — combining the design freedom of additive manufacturing with the material gentleness and formulation flexibility that pharmaceutical development demands.